These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8548417)

  • 1. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus.
    Mansfield MW; Heywood DM; Grant PJ
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):160-4. PubMed ID: 8548417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.
    Mansfield MW; Heywood DM; Grant PJ
    Circulation; 1996 Nov; 94(9):2171-6. PubMed ID: 8901668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis and diabetic retinopathy in NIDDM.
    Mansfield MW; Grant PJ
    Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease.
    Ossei-Gerning N; Wilson IJ; Grant PJ
    Thromb Haemost; 1998 Apr; 79(4):736-40. PubMed ID: 9569183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation and fibrinolysis in obese NIDDM patients.
    Avellone G; Di Garbo V; Cordova R; Rotolo G; Abruzzese G; Raneli G; De Simone R; Bompiani GD
    Diabetes Res; 1994; 25(2):85-92. PubMed ID: 7648783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
    Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.
    Carmassi F; Morale M; Puccetti R; De Negri F; Monzani F; Navalesi R; Mariani G
    Thromb Res; 1992 Sep; 67(6):643-54. PubMed ID: 1440530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
    Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
    Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
    Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
    Thromb Haemost; 1999 Mar; 81(3):367-72. PubMed ID: 10102462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.
    Avellone G; di Garbo V; Cordova R; Rotolo G; Raneli G; de Simone R; Bompiani G
    Metabolism; 1997 Aug; 46(8):930-4. PubMed ID: 9258277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic alterations with exercise conditioning in NIDDM.
    Hornsby WG; Boggess KA; Lyons TJ; Barnwell WH; Lazarchick J; Colwell JA
    Diabetes Care; 1990 Feb; 13(2):87-92. PubMed ID: 2112452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
    Sakkinen PA; Wahl P; Cushman M; Lewis MR; Tracy RP
    Am J Epidemiol; 2000 Nov; 152(10):897-907. PubMed ID: 11092431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
    Poli KA; Tofler GH; Larson MG; Evans JC; Sutherland PA; Lipinska I; Mittleman MA; Muller JE; D'Agostino RB; Wilson PW; Levy D
    Circulation; 2000 Jan; 101(3):264-9. PubMed ID: 10645922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.